DYAX CORP Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2016-03-03: Study NCT02586805; Company role Collaborator; Phase Phase 3; Status Completed.
- 2013-08-12: Study NCT01923207; Company role Collaborator; Phase Phase 1; Status Completed.
- 2013-08: Study NCT01832896; Company role Collaborator; Phase Phase 2; Status Withdrawn.
- 2010-05: Study NCT01036659; Company role Collaborator; Phase Phase 2; Status Unknown.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2016-03-03 | NCT02586805 Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE | Collaborator Lead: Shire | Phase 3 | Completed Results posted | Hereditary Angioedema (HAE) | 125 | 2017-04-13 |
| 2013-08-12 | NCT01923207 A Single Increasing Dose Study to Assess Safety and Tolerability of DX-2930 in Healthy Subjects | Collaborator Lead: Shire | Phase 1 | Completed | Hereditary Angioedema (HAE) | 32 | 2014-01-07 |
| 2013-08 | NCT01832896 Study to Assess the Tolerability and Safety of Ecallantide in Children and Adolescents With Hereditary Angioedema | Collaborator Lead: NYU Langone Health | Phase 2 | Withdrawn | Hereditary Angioedema Types I and II | 0 | 2017-12 |
| 2010-05 | NCT01036659 Evaluation of Ecallantide for the Acute Treatment of Angiotensin Converting Enzyme Inhibitor Induced Angioedema | Collaborator Lead: Bernstein, Jonathan A., M.D. | Phase 2 | Unknown | Angioedema | 50 | 2013-12 |